CD8A and cancer: Since CD8+ T-cells are capable of immunologic tumor cell destruction, CpG–ODNs have been tested both as monotherapy and as an adjuvant for cancer vaccines, against various cancer types in pre-clinical cancer models, including breast cancer (55).